Analyst Price Targets — NTRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 1:09 pm | — | Stephens | $350.00 | $317.25 | TheFly | Natera price target raised to $350 from $305 at Stephens |
| August 12, 2026 10:47 am | — | Guggenheim | $360.00 | $312.72 | TheFly | Natera price target raised to $360 from $290 at Guggenheim |
| August 10, 2026 12:33 pm | — | Morgan Stanley | $355.00 | $323.58 | TheFly | Natera price target raised to $355 from $310 at Morgan Stanley |
| August 7, 2026 12:24 pm | — | RBC Capital | $350.00 | $316.14 | TheFly | Natera price target raised to $350 from $275 at RBC Capital |
| August 7, 2026 11:56 am | Catherine Ramsey Schulte | Robert W. Baird | $348.00 | $265.38 | TheFly | Natera price target lowered to $348 from $379 at Baird |
| August 7, 2026 11:32 am | Kyle Mikson | Canaccord Genuity | $375.00 | $265.38 | TheFly | Natera price target raised to $375 from $330 at Canaccord |
| August 7, 2026 11:09 am | — | Wells Fargo | $284.00 | $265.38 | TheFly | Natera price target raised to $284 from $220 at Wells Fargo |
| August 7, 2026 10:54 am | — | BTIG | $320.00 | $265.38 | TheFly | Natera price target raised to $320 from $290 at BTIG |
| August 7, 2026 10:48 am | — | Leerink Partners | $330.00 | $265.38 | TheFly | Natera price target raised to $330 from $280 at Leerink |
| August 7, 2026 10:05 am | — | Barclays | $340.00 | $265.38 | TheFly | Natera price target raised to $340 from $260 at Barclays |
Latest News for NTRA
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their…
Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ: NTRA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,517 shares of the medical research company's stock, valued at approximately $683,000. A number of other institutional
The billionaire has good reasons to like this genetic testing leader.
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.